Clinical Trials Browser

Breast Neoplasms, Male

NCT01147016 2023-04-27

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Phase 2 Terminated

8 enrolled 7 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT03112590 2023-04-19

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

Phase 1/2 Completed

51 enrolled 13 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Phase 2 Completed

122 enrolled 22 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

NCT00622466 2020-10-19

Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer

Phase 2 Terminated

20 enrolled 8 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00513695 2019-08-07

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

Phase 2 Completed

68 enrolled 10 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00499525 2019-05-03

Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer

Phase 2 Unknown

180 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT02060253 2018-06-14

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Phase 1 Completed

9 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00482391 2017-05-12

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

Phase 2 Completed

95 enrolled 7 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01288261 2016-04-21

Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer

Phase 1 Completed

14 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00930930 2015-05-07

Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer

Phase 2 Completed

145 enrolled 10 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00680758 2013-03-08

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

Phase 1 Completed

18 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00007904 2012-10-02

Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes

Phase 2 Completed

16 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00002679 2009-08-26

Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer

Phase 2 Completed

89 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

Clinical Trials

PePPy

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer

Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes

Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer